Abstract
Patients who have not received previous antiretroviral treatment (ART) have a high failure rate on the combination treatment of abacavir, lamivudine, and tenovir. We assessed the virological failure rate in eight patients with HIV-1 who switched to this combination after having complete virological suppression from their previous long-term ART (median 8.0 months, range 7.5-18.0). Five of the eight patients showed virological failure. Four of these five patients had either the K65R mutation, the M184V/I mutation, or both. This combination of drugs cannot therefore be recommended as alternative treatment in patients with HIV-1 who are fully virologically suppressed.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Adenine / analogs & derivatives*
-
Adenine / therapeutic use
-
Antiretroviral Therapy, Highly Active
-
Dideoxynucleosides / therapeutic use
-
Drug Resistance, Multiple, Viral / genetics
-
Drug Resistance, Multiple, Viral / immunology
-
Drug Therapy, Combination
-
Genotype
-
HIV Infections / drug therapy*
-
HIV Infections / virology*
-
HIV Reverse Transcriptase / antagonists & inhibitors
-
HIV-1*
-
Humans
-
Lamivudine / therapeutic use
-
Mutation / genetics
-
Organophosphonates*
-
Organophosphorus Compounds / therapeutic use
-
Reverse Transcriptase Inhibitors / adverse effects
-
Reverse Transcriptase Inhibitors / therapeutic use*
-
Tenofovir
-
Treatment Outcome
-
Viral Load
Substances
-
Dideoxynucleosides
-
Organophosphonates
-
Organophosphorus Compounds
-
Reverse Transcriptase Inhibitors
-
Lamivudine
-
Tenofovir
-
HIV Reverse Transcriptase
-
Adenine
-
abacavir